TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8501271

Group type: EXPERIMENTAL
Intervention: 0.5% delmopinol HCl (aqueous solution)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 2960701

Group type: EXPERIMENTAL
Intervention: 10 mg loratadine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg loratadine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg loratadine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg descarboethoxyloratadine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg descarboethoxyloratadine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg descarboethoxyloratadine
Number of subjects: 12
Study: 30165429

Group type: EXPERIMENTAL
Intervention: Strong IGF1R expression
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Strong IGF1R expression in ERG-positive tumors
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Strong IGF1R expression in ERG-negative tumors
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Strong IR expression
Number of subjects: 769
Study: 27363307

Group type: EXPERIMENTAL
Intervention: Manual dietary feedback system
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Automated dietary feedback system
Number of subjects: 369
Study: 25286702

Group type: EXPERIMENTAL
Intervention: Greenlight photoselective vaporization of prostate (PVP)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Plasmakinetic resection of prostate (PRP)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both PVP and PRP
Number of subjects: 53
Study: 23072093

Group type: COMPARATOR
Intervention: Sham acupuncture (group A)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 2 Hz electroacupuncture (group B)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 2 Hz/100 Hz electroacupuncture (group C)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 100 Hz electroacupuncture (group D)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 2 Hz/100 Hz transcetaneous acupoints electrical stimulation (group E)
Number of subjects: 163
Study: 19959537

Group type: EXPERIMENTAL
Intervention: Very low cerebral blood volume (VLCBV) with a cutpoint at 2 mL and <2.5th percentile threshold
Number of subjects: 91

Group type: COMPARATOR
Intervention: Diffusion-weighted imaging (DWI) lesion volume
Number of subjects: 91

Group type: COMPARATOR
Intervention: Thresholded apparent diffusion coefficient lesion volume
Number of subjects: 91
Study: 18187242

Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-pregnant controls
Number of subjects: 30
Study: 16192258

Group type: EXPERIMENTAL
Intervention: Green tea (7 cups/day for 2 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Water (7 cups/day for 2 weeks)
Number of subjects: 22
Study: 14510091

Group type: EXPERIMENTAL
Intervention: Single dose povidone-iodine
Number of subjects: 120
Study: 10768517

Group type: EXPERIMENTAL
Intervention: Cefepime + Metronidazole (2 g cefepime + 500 mg metronidazole)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Ceftriaxone + Metronidazole (2 g ceftriaxone + 500 mg metronidazole)
Number of subjects: 615
Study: 8777468

Group type: EXPERIMENTAL
Intervention: ANF 0.004 microgram/kg/min
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ANF 0.008 microgram/kg/min
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ANF 0.016 microgram/kg/min
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vehicle (V)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ANF (all doses)
Number of subjects: 14
Study: 1325989

Group type: EXPERIMENTAL
Intervention: Prostaglandin-F2 alpha instillation into the solitary tube and systemic prostaglandin administration
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Prostaglandin treatment for tubal pregnancy
Number of subjects: 1
Study: 6664677

Group type: EXPERIMENTAL
Intervention: 1% betaxolol ophthalmic solution
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo drop
Number of subjects: 24
Study: 30669763

Group type: EXPERIMENTAL
Intervention: Low dose group (100 kV + ASIR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal dose group (120 kV + FPP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal dose group (120 kV + FBP)
Number of subjects: 100
Study: 28376345

Group type: COMPARATOR
Intervention: No variability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative timing variability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absolute timing variability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variability in both absolute and relative timing
Number of subjects: 0
Study: 26446330

Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg/kg bolus, 0.02‐0.1 mg/kg/hr infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol (1 mg/kg bolus, 1‐3 mg/kg/hr infusion)
Number of subjects: 60
Study: 24095618

Group type: EXPERIMENTAL
Intervention: Pregabalin 200mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19022622

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 24
Study: 17542016

Group type: EXPERIMENTAL
Intervention: Tablet A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tablet B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capsule
Number of subjects: 0
Study: 16335333

Group type: EXPERIMENTAL
Intervention: Valerian-hops combination (2 nightly tablets for 28 days, n = 59)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (2 tablets of 25 mg for 14 days followed by placebo for 14 days, n = 60)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo (for 28 days, n = 65)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Valerian-hops combination (n = 59)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (n = 60)
Number of subjects: 184
Study: 12172357

Group type: EXPERIMENTAL
Intervention: IN midazolam (n = 30)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IV midazolam (n = 28)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (n = 23)
Number of subjects: 81
Study: 10446797

Group type: EXPERIMENTAL
Intervention: Ureteroscopy
Number of subjects: 40
Study: 7588824

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Zidovudine (no mutation)
Number of subjects: 38
Study: 2178660

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg and 800 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Frusemide (administered after baseline measurements)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control for indomethacin)
Number of subjects: 8
Study: 92062

Group type: EXPERIMENTAL
Intervention: 0.3% pyrethrins synergized by 3.0% piperonyl butoxide (RiD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1% gamma-benzene hexachloride (Kwell)
Number of subjects: 30
Study: 31117807

Group type: EXPERIMENTAL
Intervention: Ability to resist social pressure to use tobacco/betel nut
Number of subjects: 2449

Group type: EXPERIMENTAL
Intervention: Current cigarette use among middle school students
Number of subjects: 2449

Group type: EXPERIMENTAL
Intervention: Current smokeless tobacco use among middle school students
Number of subjects: 2449

Group type: EXPERIMENTAL
Intervention: Current e-cigarette use among middle school students
Number of subjects: 2449

Group type: EXPERIMENTAL
Intervention: Indigenous Pacific Islanders
Number of subjects: 2449
Study: 28345790

Group type: EXPERIMENTAL
Intervention: Acyl ghrelin infusion (1 pmol kg-1 min-1)
Number of subjects: 18
Study: 26444729

Group type: EXPERIMENTAL
Intervention: Daclizumab HYP (150 mg subcutaneously every 4 weeks)
Number of subjects: 1841

Group type: COMPARATOR
Intervention: Interferon beta-1a (30 μg intramuscularly once weekly)
Number of subjects: 1841

Group type: EXPERIMENTAL
Intervention: Daclizumab HYP
Number of subjects: 1841

Group type: COMPARATOR
Intervention: Interferon beta-1a
Number of subjects: 1841
Study: 23667440

Group type: EXPERIMENTAL
Intervention: Guideline-based ontology development training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Basic principles of formal ontology engineering training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Differential training on topics in ontology development
Number of subjects: 24
Study: 21131201

Group type: EXPERIMENTAL
Intervention: Lycra(®) splint wear for three months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 16
Study: 19752420

Group type: EXPERIMENTAL
Intervention: 1-mg intravitreal triamcinolone
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: 4-mg intravitreal triamcinolone
Number of subjects: 411

Group type: COMPARATOR
Intervention: Standard care (grid photocoagulation)
Number of subjects: 411
Study: 16924272

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 3.2 g/day for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15049885

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly
Number of subjects: 487

Group type: COMPARATOR
Intervention: Raloxifene 60 mg daily
Number of subjects: 487
Study: 11715619

Group type: EXPERIMENTAL
Intervention: Selective bowel decontamination with tobramycin, polymyxin B and amphotericin B
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no selective bowel decontamination)
Number of subjects: 70
Study: 12515414

Group type: EXPERIMENTAL
Intervention: NCEP step 2 diet
Number of subjects: 364
Study: 8048199

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia only (EA, n = 34)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia (EG, n = 33)
Number of subjects: 98

Group type: COMPARATOR
Intervention: General anesthesia only (GA, n = 31)
Number of subjects: 98
Study: 2730822

Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline 1 in 200,000
Number of subjects: 80

Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 80
Study: 1123897

Group type: EXPERIMENTAL
Intervention: Sorbitol infusion at 0.125 g/kg/h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sorbitol infusion at 0.25 g/kg/h
Number of subjects: 20
Study: 31003654

Group type: EXPERIMENTAL
Intervention: Lavender oil inhalation (1:10 ratio of lavender and sweet almond oil)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no lavender oil inhalation)
Number of subjects: 60
Study: 28420673

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Seated rest
Number of subjects: 30
Study: 25486371

Group type: EXPERIMENTAL
Intervention: Listening Visits (LV)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Wait-list control group (WLC)
Number of subjects: 66
Study: 23708942

Group type: EXPERIMENTAL
Intervention: IIH patients
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study: 21870630

Group type: EXPERIMENTAL
Intervention: Low-calorie diet including 30 g day(‐1) of soy protein
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (low-calorie diet without soy protein)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low-calorie diet
Number of subjects: 52
Study: 19702850

Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri OLL2716 (LG21) containing cheese
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo (ordinary cheese)
Number of subjects: 440
Study: 16498362

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs) such as Anastrozole, Letrozole, and Exemestane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 0
Study: 12969362

Group type: EXPERIMENTAL
Intervention: Brånemark implants
Number of subjects: 25

Group type: COMPARATOR
Intervention: ITI implants
Number of subjects: 25
Study: 10714567

Group type: EXPERIMENTAL
Intervention: Ritonavir (n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 21
Study: 9198260

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 1526392

Group type: EXPERIMENTAL
Intervention: Lactulose in the postprandial period
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lactitol in the postprandial period
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lactulose in the fasting state
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lactitol in the fasting state
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both disaccharides (lactulose and lactitol)
Number of subjects: 12
Study: 3931144

Group type: COMPARATOR
Intervention: 5 mg diazepam
Number of subjects: 36

Group type: COMPARATOR
Intervention: 10 mg diazepam
Number of subjects: 36

Group type: COMPARATOR
Intervention: 5 mg d,l-amphetamine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: amphetamine
Number of subjects: 36
Study: 30043434

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5 mg/kg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg/kg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Paracetamol 20 mg/kg
Number of subjects: 210
Study: 28394012

Group type: EXPERIMENTAL
Intervention: Non-ischemic and non-hypertensive heart failure management
Number of subjects: 5563

Group type: EXPERIMENTAL
Intervention: Implanted CRT-D and ICD
Number of subjects: 5563

Group type: EXPERIMENTAL
Intervention: Heart failure of non-ischemic and non-hypertensive origin
Number of subjects: 5563
Study: 26987376

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 43

Group type: COMPARATOR
Intervention: PI/r switching
Number of subjects: 43
Study: 24887013

Group type: EXPERIMENTAL
Intervention: Plant sterols (2 g daily)
Number of subjects: 59
Study: 22346753

Group type: EXPERIMENTAL
Intervention: Experimental hookworm infection
Number of subjects: 0
Study: 20624140

Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg IV followed by 0.5 mg/kg every 3 minutes as needed
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ketamine 1.0 mg/kg IV followed by 0.5 mg/kg every 3 minutes as needed
Number of subjects: 100
Study: 17898702

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell therapy (MSCs)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 11814216

Group type: EXPERIMENTAL
Intervention: Contextual Distinctiveness (CD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Occurrence Frequency
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concreteness, Context Availability, Number of Contexts, Ambiguity, Age of Acquisition, Familiarity
Number of subjects: 0
Study: 9489908

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg twice daily) and Amoxicillin (750 mg three times daily)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Omeprazole (40 mg twice daily) and Placebo (750 mg three times daily)
Number of subjects: 158
Study: 7917910

Group type: EXPERIMENTAL
Intervention: Cisplatinum (50 mg m‐2) with ondansetron (8 mg i.v. x 3 at chemotherapy and 8 mg p.o. x 3 for 5 days)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Low or moderately emetogenic chemotherapy
Number of subjects: 62
Study: 3070048

Group type: EXPERIMENTAL
Intervention: Family-based health promotion program (1-year intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control families
Number of subjects: 60
Study: 31648988

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell injections (MSCs)
Number of subjects: 34
Study: 28514784

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (80 mg of rosuvastatin loading followed by 40 mg daily)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard statin therapy (usual-care group)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (in patients with abnormal glucose tolerance)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard statin therapy (in patients with abnormal glucose tolerance)
Number of subjects: 140
Study: 25931419

Group type: EXPERIMENTAL
Intervention: Actazin high dose (Actazin-H) [2400 mg/day]
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Gold [2400 mg/day]
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Actazin low dose (Actazin-L) [600 mg/day]
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 23743088

Group type: EXPERIMENTAL
Intervention: TREAT decision support system for antibiotic treatment (intervention arm)
Number of subjects: 1683

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 1683
Study: 21983496

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: Anxiolytics
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: Sedative/hypnotics
Number of subjects: 1449
Study: 20182958

Group type: EXPERIMENTAL
Intervention: Care Transitions Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 17150155

Group type: EXPERIMENTAL
Intervention: Animal models of AAA
Number of subjects: 0
Study: 15293891

Group type: EXPERIMENTAL
Intervention: CEE (Conjugated Estrogen)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CEE + MPA (Conjugated Estrogen + Medroxyprogesterone Acetate)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 150
Study: 11203790

Group type: EXPERIMENTAL
Intervention: Silux Plus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Z100
Number of subjects: 60
Study: 9133173

Group type: EXPERIMENTAL
Intervention: 1:1 mixture of plain 0.5% bupivacaine and hyperbaric 4% mepivacaine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Hyperbaric 0.5% bupivacaine
Number of subjects: 122
Study: 8380291

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 30850896

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 20
Study: 28475816

Group type: EXPERIMENTAL
Intervention: Anakinra (recombinant human IL-1 receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26620271

Group type: EXPERIMENTAL
Intervention: Pulmonary wedge resection plus parietal pleurectomy (WRPP)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Parietal pleurectomy (PP)
Number of subjects: 360
Study: 23647728

Group type: EXPERIMENTAL
Intervention: 5-factor model of PTSD
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 4-factor dysphoria model
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 4-factor emotional numbing model
Number of subjects: 151

Group type: COMPARATOR
Intervention: 3-factor model of PTSD
Number of subjects: 151
Study: 21132451

Group type: EXPERIMENTAL
Intervention: 5-FU/PEG-IFN group
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5-FU/IFN group
Number of subjects: 50

Group type: COMPARATOR
Intervention: CDDP group
Number of subjects: 50
Study: 18206361

Group type: EXPERIMENTAL
Intervention: FSC 250/50 mcg once daily
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: FP 250 mcg once daily
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: FSC 100/50 mcg twice daily
Number of subjects: 844

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 844
Study: 16529615

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 500 mg bid, titrated to 1,000 mg bid
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 15470802

Group type: EXPERIMENTAL
Intervention: Paroxetine + Lamotrigine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paroxetine + Placebo
Number of subjects: 40
Study: 11299228

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg once daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Losartan and Placebo
Number of subjects: 27
Study: 9303380

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg once daily on days 16-30)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Delavirdine mesylate (300 mg every 8 hours for 30 days)
Number of subjects: 13
Study: 8417428

Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg/day daily)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cefaclor (40 mg/kg/day divided into two doses)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 108
Study: 3752963

Group type: EXPERIMENTAL
Intervention: AM3 (biological response modifier) with adjuvant radiotherapy and chemotherapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (adjuvant radiotherapy and chemotherapy without AM3)
Number of subjects: 46
Study: 29943350

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg once daily plus a P2Y12 inhibitor (N=696)
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy (DAPT) (N=706)
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Warfarin plus DAPT (N=697)
Number of subjects: 2099
Study: 25871479

Group type: EXPERIMENTAL
Intervention: Recovery at 1667 m
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recovery at 3333 m
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recovery at 5000 m
Number of subjects: 12

Group type: COMPARATOR
Intervention: Recovery at 0 m
Number of subjects: 12
Study: 25130629

Group type: EXPERIMENTAL
Intervention: Liquid nutritional supplement (Nutrisen) with increased whey protein (200 ml daily for 8 weeks)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Liquid nutritional supplement (Nutrisen)
Number of subjects: 47
Study: 22260233

Group type: EXPERIMENTAL
Intervention: baby wipes
Number of subjects: 44

Group type: COMPARATOR
Intervention: water-moistened washcloth
Number of subjects: 44
Study: 20937162

Group type: EXPERIMENTAL
Intervention: C. longa (6 g)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 18782799

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with low-dosage Mitomycin-C (MMC) (0.2 mg/ml, 2 min application)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with low-dosage Mitomycin-C (MMC)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Trabeculectomy with balanced saline solution (BSS)
Number of subjects: 114